Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 |
| NCT06124118 | Tumor Treating Fields for Locally Advanced NSCLC(NOVOCURE) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT06434103 | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | withdrawn | Phase 1 / Phase 2 | 0 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 8, 2026 | clinicaltrials |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | withdrawn | Phase 1 / Phase 2 | 0 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05488626 | Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer(ARTIA-Lung) | withdrawn | N/A | 0 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05472623 | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab(Neo-Kan) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT00210171 | Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer(BIB 01) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06676917 | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases(TUXEDO-5) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT04615884 | Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients(CH:II) | withdrawn | N/A | 0 | Lady Davis InstituteOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05840770 | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 26, 2025 | clinicaltrials |
| NCT03877250 | Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06522360 | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT04485026 | Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 17, 2025 | clinicaltrials |
| NCT05648188 | A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells(LUNGadenosine) | withdrawn | — | 0 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | withdrawn | Phase 1 | 0 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06075615 | A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain. | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Feb 7, 2025 | clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT05094544 | Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC(POIMS) | withdrawn | N/A | 0 | University of Kansas Medical CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC(AMBER) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 4 | Nov 20, 2024 | clinicaltrials |
| NCT04987281 | Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer(BOUNCE) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 5 | Oct 8, 2024 | clinicaltrials |
| NCT06427369 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Sep 27, 2024 | clinicaltrials |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors(SPICE) | withdrawn | — | 0 | University of CologneOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05757843 | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06064279 | Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC(HAITEN-ICI) | withdrawn | Phase 1 / Phase 2 | 0 | VA Office of Research and DevelopmentFED | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | withdrawn | Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05364645 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02840227 | The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections | withdrawn | N/A | 0 | The Cleveland ClinicOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05567055 | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | withdrawn | Phase 2 | 0 | Timothy Burns, MD, PHDOTHER | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06331585 | Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy | withdrawn | Phase 2 | 0 | Hetian District People's HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Kartos Therapeutics, Inc.INDUSTRY | 0 | Mar 22, 2024 | clinicaltrials |
| NCT04102436 | Non-Viral TCR Gene Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients(XQonc-007) | withdrawn | Phase 2 | 0 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | withdrawn | Phase 2 | 0 | Advaxis, Inc.INDUSTRY | 0 | Dec 19, 2023 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials